US 11,814,426 B2
Anti-tenascin C antibodies and uses thereof
Kim Suzanne Midwood, Buckinghamshire (GB); Philip Antony Bland-Ward, Marlow (GB); Nigel Burns, Marlow (GB); Patrick John Hextall, Cambridge (GB); and Susan Rebecca Aungier, Oxford (GB)
Assigned to STERLING IP LIMITED
Filed by STERLING IP LIMITED, Marlow (GB)
Filed on Apr. 13, 2021, as Appl. No. 17/301,741.
Application 17/301,741 is a continuation of application No. 16/707,157, filed on Dec. 9, 2019, granted, now 11,008,384.
Application 16/707,157 is a continuation of application No. 16/104,610, filed on Aug. 17, 2018, granted, now 10,533,047, issued on Jan. 14, 2020.
Application 16/104,610 is a continuation of application No. 15/501,979, granted, now 10,093,723, issued on Oct. 9, 2018, previously published as PCT/GB2015/052298, filed on Aug. 7, 2015.
Claims priority of application No. 1414021 (GB), filed on Aug. 7, 2014.
Prior Publication US 2021/0355201 A1, Nov. 18, 2021
Int. Cl. A61K 39/395 (2006.01); A61K 39/00 (2006.01); C07K 16/18 (2006.01); G01N 33/68 (2006.01); C07K 14/78 (2006.01)
CPC C07K 16/18 (2013.01) [A61K 39/3955 (2013.01); C07K 14/78 (2013.01); G01N 33/6893 (2013.01); A61K 2039/505 (2013.01); C07K 2317/33 (2013.01); C07K 2317/55 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/567 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2319/30 (2013.01)] 24 Claims
 
1. A method of treating cancer comprising administering to a subject an effective amount of an anti-fibrinogen-like globe (FBG) domain of a tenascin-C antibody or antigen binding fragment thereof, comprising a VH region wherein CDRH1 is SEQ ID NO: 9, CDRH2 is SEQ ID NO: 10, CDRH3 is independently selected from SEQ ID NO: 11, 30, 32, 34, 36, 38, 40, 42, 44, and 46, and a VL region wherein a CDRL1 is SEQ ID NO: 5, CDRL2 is SEQ ID NO: 13 and CDRL3 is SEQ ID NO: 14.